Lipocine Inc. is a biopharmaceutical company that develops oral drug delivery solutions for molecules with poor bioavailability. Its proprietary technology platform utilizes lipidic compositions to form optimal dispersed phases in the gastrointestinal tract, enhancing the absorption of water-insoluble drugs. The company's primary commercial product is TLANDO, an oral treatment for testosterone replacement therapy approved by the FDA in 2022. Lipocine has licensed the commercialization rights for TLANDO to Verity Pharmaceuticals for the U.S. and Canada, SPC Korea for South Korea, Pharmalink for the Gulf Cooperation Council countries, and Aché for Brazil. The company's clinical pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2203 for essential tremor. Additional development candidates target liver cirrhosis, obesity management, and the prevention of recurrent preterm birth. Lipocine also holds rights to LPCN 1111, a next-generation once-daily oral testosterone replacement therapy candidate.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lipocine.com
Sector Healthcare IR page ir.lipocine.com
Tags
oral drug delivery, testosterone replacement therapy, postpartum depression, major depressive disorder, epilepsy, essential tremor, liver cirrhosis, obesity management, preterm birth prevention, lipidic compositions, neurological disorders, psychiatric disorders, TLANDO, LPCN 1111, TLANDO XR, LPCN 1154, BRLIZIO, LPCN 2201, LPCN 2101, LPCN 2203, LPCN 1148, LPCN 2401, LPCN 1107, Verity Pharmaceuticals, SPC Korea, Pharmalink, Aché
Press page ir.lipocine.com/press-releases

Metrics

Valuation  
Market cap $ 13.192M
Market cap (USD) $ 13.192M
P/E -1.25
PEG —
P/BV 0.62
P/S 4.46
P/OCF -1.32
P/FCF -1.35
Dividend yield —
Turnover / mcap —
Returns  
ROE -54.3%
ROI -66.5%
ROIC -53.7%
Profit margin -487.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -68.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Revenue 1.977M 11.198M -2.851M 500K 16.141M 0 164.99K 428.031K — — — — 0 — —
Net profit -9.628M 8.352K -16.352M -10.759M -634.399K -20.965M -13.007M -11.66M -20.983M -18.972M -18.208M -20.373M -10.59M -76.654K -5.162K
Free cash flow -9.761M -1.311M -11.879M -12.103M -4.419M — — -12.079M -16.702M -18.342M -15.385M -17.364M -8.59M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Share price 8.03 4.88 2.79 0.4 0.99 1.36 0.38 1.3 3.44 3.68 12.93 5.26 — — —
Price performance 12m 0.65 0.75 6.01 -0.6 -0.27 2.54 -0.7 -0.62 -0.07 -0.72 1.46 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — 0.00 3.33M 3.33M 3.33M 2.31M — — — —
Borrowings, non-current (USD) — 0.00 6.93M 3.81M 2.26M — — — — —
Cash and deposits (USD) 5.56M 3.21M 8.08M 9.73M 19.2M 2.95M 3.15M 4.77M 6.21M 5.21M
Net debt (borrowings + leases - cash) (USD) — -3.21M 2.18M -2.58M -13.6M -639,727 — — — —
Cash flow detail
Operating cash flow (USD) -18.3M -16.7M -12.1M -11.7M -15.3M -4.41M -12M -11.9M -1.22M -9.76M
Purchases of property, plant and equipment (USD) -59,650 0.00 0.00 — — -7,591 -133,831 -13,167 -90,086 —
Change in payables (cash effect) (USD) -261,152 352,155 73,210 510,961 414,979 -307,878 -688,954 795,589 -1.12M 700,126
Interest paid (cash effect) (USD) 0.00 0.00 -533,542 -545,536 -276,019 -149,543 -21,256 — — —
Income taxes paid (cash effect) (USD) -752 -700 -700 -700 -200 -200 -200 -225 -681 -200
Share-based compensation (USD) 2.37M 2.72M 1.46M 1.04M 1.37M 603,946 636,140 654,438 408,551 242,497
Free cash flow (OCF - PPE - intangibles) (USD) -18.3M -16.7M -12.1M — — -4.42M -12.1M -11.9M -1.31M —
Income detail
Research and development expense (USD) 8.08M 11M 6.46M 7.47M 9.75M 7.67M 8.56M 10.2M 7.35M 8.58M
↳ 5y CAGR +37.0% +4.8% -13.6% -5.0% -1.0% -4.9% +9.5% -0.3% -2.5%
Total comprehensive income (USD) -18.9M -21M -11.7M -13M -21M -652,415 -10.8M -16.3M 10,231 -9.63M
Comprehensive income to owners (USD) -18.9M -21M -11.7M -13M -21M -652,415 -10.8M -16.3M 10,231 -9.63M
Reported Mar 6, 2019 Mar 6, 2019 Mar 6, 2019 Mar 13, 2020 Mar 11, 2021 Mar 9, 2022 Mar 10, 2023 Mar 7, 2024 Mar 13, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

● LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depression

● Approximately 120 participants planned for the study, which incorporates insights from the previous Phase 3 trial to promote site and data quality

● Topline results from BLOOM study are expected in 2H 2027

SALT LAKE CITY, November 10, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company’s Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD). LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use.

First participant dosing marks the start of treatment in BLOOM and advances Lipocine’s LPCN 1154 clinical development program towards a potential NDA submission. The placebo-controlled outpatient study is designed to evaluate efficacy and safety and complement the existing clinical data package in support of a potential New Drug Application (NDA) under the 505(b)(2) pathway. Topline results from the BLOOM study are expected in 2H 2027.

SALT LAKE CITY, Nov. 5, 2026 /PRNewswire / -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.

Recent Developments and Corporate Update

LPCN 1154 (BRLIZIO™) for Postpartum Depression (PPD)

In September 2026, Lipocine announced the initiation of the BLOOM (Brexanolone Lifting Outcomes of Moms) study.  The Phase 3 placebo-controlled outpatient study is expected to enroll approximately 120 participants with PPD and is designed to generate prospective efficacy and safety evidence to support a potential New Drug Application (NDA) under the 505(b)(2) pathway. Feedback from a recent meeting with the FDA, including the necessity of a positive and well-controlled Phase 3 trial, together with learnings from the prior Phase 3 trial, are incorporated into the BLOOM study design. Further, feedback from the FDA acknowledged that the NDA submission package presented to FDA appears complete to support 505(b)(2) NDA submission with the exception of the need for a single positive and well controlled Phase 3 trial.

  • Lipocine continues to explore business partnerships for the development, approval and commercialization of BRLIZIO™ (LPCN 1154).

Other Neuroactive Steroid Programs

  • LPCN 2201 for Major Depressive Disorder (MDD): Following planned clinical assessment of unique oral brexanolone formulations, Lipocine plans to submit a Phase 2 protocol to the FDA and may initiate a study of LPCN 2201 in MDD, subject to resource prioritization.
  • LPCN 2203 for Essential Tremor (ET): Lipocine has completed oral pharmacokinetic studies of LPCN 2203 and plans to submit a protocol for a proof-of-concept Phase 2 study in essential tremor to the FDA. Any future studies of LPCN 2203 will be subject to resource prioritization. 

TLANDO®

  • In September 2026, Health Canada approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity Pharma, Lipocine's partner in North America, is planning for launch in Canada in early 2027.
  • In July 2026, Lipocine's distribution partner Pharmalink received product marketing authorization approval in the United Arab Emirates for TESTYRA® (TLANDO). Pharmalink is planning for launch in the UAE in early 2027.
  • Lipocine continues to explore partnering TLANDO in territories outside the U.S., Canada, South Korea, the GCC countries and Brazil.

Third Quarter Ended September 30, 2026 Financial Results

As of September 30, 2026, Lipocine had $21.5 million of unrestricted cash, cash equivalents and marketable investment securities, compared to $14.9 million at December 31, 2025. As of November 4, 2026, the Company had approximately $28.5 million of unrestricted cash, cash equivalents and marketable investment securities (unaudited).

Lipocine reported a net loss of $0.7 million, or ($0.08) per diluted share, for the quarter ended September 30, 2026, compared to a net loss of $3.2 million, or ($0.59) per diluted share, for the quarter ended September 30, 2025.

Lipocine recognized total revenue of $2.3 million during the quarter ended September 30, 2026, compared to $115,000 during the quarter ended September 30, 2025. Revenue for the third quarter of 2026 consisted of license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $190,000. Revenue for the third quarter of 2025 consisted entirely of royalty revenue from TLANDO sales.

Research and development expenses were $2.1 million and $2.7 million, respectively, for the quarters ended September 30, 2026 and 2025. The decrease primarily reflects lower costs related to the LPCN 2401 study, which was placed on hold in 2025, and lower LPCN 1154 clinical costs in 2026 compared with costs incurred for the prior Phase 3 study during the third quarter of 2025, partially offset by an increase in personnel costs.

General and administrative expenses were $1.1 million and $0.8 million, respectively, for the quarters ended September 30, 2026 and 2025. The increase primarily reflects higher personnel costs and higher legal fees related to protecting the Company's intellectual property and promoting its corporate strategy.

Interest and investment income was $0.2 million for each of the quarters ended September 30, 2026 and 2025.

Nine Months Ended September 30, 2026 Financial Results

Lipocine reported a net loss of $7.0 million, or ($0.90) per diluted share, for the nine months ended September 30, 2026, compared to a net loss of $7.3 million, or ($1.35) per diluted share, for the nine months ended September 30, 2025.

Lipocine recognized revenue of $2.6 million and $831,000 during the nine months ended September 30, 2026 and 2025, respectively. Revenue for the 2026 period consisted of license and collaboration revenue of $2.1 million and royalty revenue from TLANDO sales of $500,000. Revenue for the 2025 period consisted of license revenue of $500,000 and royalty revenue from TLANDO sales of $331,000.

Research and development expenses were $6.9 million and $5.9 million, respectively, for the nine-month periods ended September 30, 2026 and 2025. The increase primarily reflects higher costs related to LPCN 1154 studies and other clinical trial costs, as well as an increase in personnel expense.

General and administrative expenses were $3.3 million and $2.8 million, respectively, for the nine-month periods ended September 30, 2026 and 2025. The increase primarily reflects higher legal fees related to protecting the Company's intellectual property and promoting its corporate strategy, as well as an increase in personnel expense.

Interest and investment income was $0.6 million for each of the nine-month periods ended September 30, 2026 and 2025.

For further detail on Lipocine's financial results for the three and nine months ended September 30, 2026, refer to the Company's Form 10-Q filed with the SEC.

About Lipocine

Lipocine is a biopharmaceutical company developing oral therapeutics using its proprietary drug-delivery technology platform. The Company advances product candidates addressing significant unmet medical needs and explores partnerships to support their development and commercialization.

Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com .

Forward Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of our products and product candidates and related efforts with the FDA, including the design, planned enrollment, timing and potential outcomes of the BLOOM study; the sufficiency of existing financial and operational resources to execute the study; expected average monthly cash use, study expenditures and cash needs; the timing of clinical trials and regulatory submissions; the timing of anticipated commercial launches of licensed products; the potential uses and benefits of our products and product candidates; the commercial potential for our product candidates; and potential strategic partnerships and other opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of an NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, variability in enrollment and site performance, study costs exceeding current estimates, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov . Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
September 30, December 31,
2026 2025
Current assets:
Cash and cash equivalents $              25,94,151 $         52,05,842
Marketable investment securities 1,88,61,297 97,24,545
Accrued interest income 2,08,462 14,189
License fee and royalties receivable 6,90,071 11,45,390
Prepaid and other current assets 7,58,676 7,87,600
Total current assets 2,31,12,657 1,68,77,566
Property and equipment, net of accumulated depreciation
of $1,328,188 and $1,284,079 respectively 60,184 1,04,293
Other assets 23,753 23,753
Total assets $           2,31,96,594 $      1,70,05,612
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $                5,44,347 $          9,71,822
Accrued expenses 11,70,099 12,36,374
Deferred revenue 3,20,000 3,20,000
Total current liabilities 20,34,446 25,28,196
Total liabilities 20,34,446 25,28,196
Commitments and contingencies
Stockholders' equity:
Common stock, par value $0.0001 per share, 75,000,000
shares authorized; 8,245,798 and 6,158,779 issued and
8,245,462 and 6,158,443 outstanding, respectively 9,153 8,944
Additional paid-in capital 23,75,77,314 22,39,01,106
Treasury stock at cost, 336 shares (40,712) (40,712)
Accumulated other comprehensive income (26,559) 4,445
Accumulated deficit (21,63,57,048) (20,93,96,367)
Total stockholders' equity 2,11,62,148 1,44,77,416
Total liabilities and stockholders' equity $           2,31,96,594 $      1,70,05,612
LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenues:
License revenue $            21,00,000 $                       - $            21,00,000 $             5,00,000
Royalty revenue 1,90,072 1,14,574 4,99,568 3,31,287
Total revenues 22,90,072 1,14,574 25,99,568 8,31,287
Operating expenses:
Research and development 20,70,033 27,07,777 68,75,816 59,06,118
General and administrative 10,88,564 7,67,837 32,83,987 27,80,747
Total operating expenses 31,58,597 34,75,614 1,01,59,803 86,86,865
Operating loss (8,68,525) (33,61,040) (75,60,235) (78,55,578)
Other income:
Interest and investment income 2,02,333 1,74,208 5,99,754 5,98,357
Total other income 2,02,333 1,74,208 5,99,754 5,98,357
Loss before income tax expense (6,66,192) (31,86,832) (69,60,481) (72,57,221)
Income tax expense - - (200) (200)
Net loss attributable to common shareholders $            (6,66,192) $         (31,86,832) $          (69,60,681) $         (72,57,421)
Basic loss per share attributable to common stock $                  (0.08) $                 (0.59) $                  (0.90) $                 (1.35)
Weighted average common shares outstanding, basic 82,44,542 54,13,149 77,57,487 53,71,458
Diluted loss per share attributable to common stock $                  (0.08) $                 (0.59) $                  (0.90) $                 (1.35)
Weighted average common shares outstanding, diluted 82,44,542 54,13,149 77,57,487 53,71,458
Comprehensive loss:
Net loss $            (6,66,192) $         (31,86,832) $          (69,60,681) $         (72,57,421)
Net unrealized gain (loss) on marketable investment securities (13,158) 5,870 (31,004) (4,511)
Comprehensive loss $            (6,79,350) $         (31,80,962) $          (69,91,685) $         (72,61,932)

SOURCE Lipocine Inc.

Lipocine Inc. — Other Events Bull 0 Bear 0 Routine

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.

Prompts

Lipocine Inc. (ticker LPCN), listed in United States.

Company History

Date Change Detail
Jul 25, 2013 Renamed MARATHON BAR CORP → LIPOCINE INC.

ETFs Holding Lipocine Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 5,180 $ 8,391.60 Nov 12, 2026
DXUV 0.00% 2,156 $ 3,492.72 Nov 12, 2026
DCOR 0.00% 5,116 $ 8,287.92 Nov 12, 2026
DFAC 0.00% 4,792 $ 7,763.04 Nov 12, 2026